KR20240019083A - 트리아진 유도체 및 암 치료에서 이의 용도 - Google Patents

Info

Publication number

KR20240019083A

KR20240019083A KR1020237039328A KR20237039328A KR20240019083A KR 20240019083 A KR20240019083 A KR 20240019083A KR 1020237039328 A KR1020237039328 A KR 1020237039328A KR 20237039328 A KR20237039328 A KR 20237039328A KR 20240019083 A KR20240019083 A KR 20240019083A

Authority

KR

South Korea

Prior art keywords

methyl

triazin

amino

piperidyl

phenol

Prior art date

2021-06-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims description 31
• 206010028980 Neoplasm Diseases 0.000 title description 7
• 201000011510 cancer Diseases 0.000 title description 7
• 150000003918 triazines Chemical class 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 289
• 238000000034 method Methods 0.000 claims abstract description 37
• 125000000217 alkyl group Chemical group 0.000 claims description 119
• -1 -OH Chemical group 0.000 claims description 100
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 90
• 125000005843 halogen group Chemical group 0.000 claims description 86
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 77
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 72
• 125000001188 haloalkyl group Chemical group 0.000 claims description 71
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 60
• 150000003839 salts Chemical class 0.000 claims description 47
• 201000010099 disease Diseases 0.000 claims description 45
• 208000035475 disorder Diseases 0.000 claims description 45
• 125000005842 heteroatom Chemical group 0.000 claims description 45
• 125000000623 heterocyclic group Chemical group 0.000 claims description 45
• 125000004429 atom Chemical group 0.000 claims description 43
• 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims description 40
• 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims description 40
• 125000001424 substituent group Chemical group 0.000 claims description 38
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 24
• 238000006243 chemical reaction Methods 0.000 claims description 22
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 21
• 208000006673 asthma Diseases 0.000 claims description 21
• 230000002265 prevention Effects 0.000 claims description 20
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 18
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 18
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 13
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 150000002825 nitriles Chemical class 0.000 claims description 11
• 239000003814 drug Substances 0.000 claims description 10
• 230000005764 inhibitory process Effects 0.000 claims description 10
• ZOVSPJPKTYFFOS-CYBMUJFWSA-N CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 ZOVSPJPKTYFFOS-CYBMUJFWSA-N 0.000 claims description 9
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 9
• 229910052763 palladium Inorganic materials 0.000 claims description 7
• GATKHKSVRDWAJC-GFCCVEGCSA-N CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H]2CN(C)CCC2)=N1 Chemical compound CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H]2CN(C)CCC2)=N1 GATKHKSVRDWAJC-GFCCVEGCSA-N 0.000 claims description 6
• LKKMIAUQQWDANW-GFCCVEGCSA-N CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC(OC(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC(OC(F)(F)F)=C2)=C2O)N=N1 LKKMIAUQQWDANW-GFCCVEGCSA-N 0.000 claims description 6
• VSAYABPTYHGOKM-OAHLLOKOSA-N CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC2=C3CCC2)=C3O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC2=C3CCC2)=C3O)N=N1 VSAYABPTYHGOKM-OAHLLOKOSA-N 0.000 claims description 6
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 claims description 5
• 239000003054 catalyst Substances 0.000 claims description 5
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
• RMUUAUQMGZBCIS-UHFFFAOYSA-N CC(C1)(CC1NC1=NC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1)O Chemical compound CC(C1)(CC1NC1=NC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1)O RMUUAUQMGZBCIS-UHFFFAOYSA-N 0.000 claims description 4
• MFPWDNHCYYAGQZ-UHFFFAOYSA-N CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(NC2C3=NC=CN3CCC2)=N1 Chemical compound CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(NC2C3=NC=CN3CCC2)=N1 MFPWDNHCYYAGQZ-UHFFFAOYSA-N 0.000 claims description 4
• ZPMRUKBQXRUFHV-GFCCVEGCSA-N CC1=C(C(C=CC(Cl)=C2)=C2O)N=NC(N[C@H]2CN(C)CCC2)=N1 Chemical compound CC1=C(C(C=CC(Cl)=C2)=C2O)N=NC(N[C@H]2CN(C)CCC2)=N1 ZPMRUKBQXRUFHV-GFCCVEGCSA-N 0.000 claims description 4
• HQMXJOXAJQCQHP-UHFFFAOYSA-N CCN(CCC1)CC1NC1=NC(C)=C(C(C=CC(Cl)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)CC1NC1=NC(C)=C(C(C=CC(Cl)=C2)=C2O)N=N1 HQMXJOXAJQCQHP-UHFFFAOYSA-N 0.000 claims description 4
• QBIGVEGZMBGODX-CQSZACIVSA-N CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC(C#N)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C=CC(C#N)=C2)=C2O)N=N1 QBIGVEGZMBGODX-CQSZACIVSA-N 0.000 claims description 4
• ARCKATRCYFGUKS-CYBMUJFWSA-N CCN(CCC1)C[C@@H]1NC1=NC=C(C(C(C)=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC=C(C(C(C)=CC(C(F)(F)F)=C2)=C2O)N=N1 ARCKATRCYFGUKS-CYBMUJFWSA-N 0.000 claims description 4
• 239000013543 active substance Substances 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
• XOGZKCWOFATONB-GFCCVEGCSA-N CC1=C(C(C=CC(F)=C2)=C2O)N=NC(N[C@H]2CN(C)CCC2)=N1 Chemical compound CC1=C(C(C=CC(F)=C2)=C2O)N=NC(N[C@H]2CN(C)CCC2)=N1 XOGZKCWOFATONB-GFCCVEGCSA-N 0.000 claims description 3
• AKYAPBXIEYQJQG-UHFFFAOYSA-N CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(NC2C(CCC3)N3CCC2)=N1 Chemical compound CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(NC2C(CCC3)N3CCC2)=N1 AKYAPBXIEYQJQG-UHFFFAOYSA-N 0.000 claims description 2
• LNKDDLQDUAFGGS-NWDGAFQWSA-N CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H](C2)CN(C)C[C@H]2F)=N1 Chemical compound CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H](C2)CN(C)C[C@H]2F)=N1 LNKDDLQDUAFGGS-NWDGAFQWSA-N 0.000 claims description 2
• ZMKKDSQSTGFJGN-CHWSQXEVSA-N CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H](CCCC2)[C@@H]2O)=N1 Chemical compound CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H](CCCC2)[C@@H]2O)=N1 ZMKKDSQSTGFJGN-CHWSQXEVSA-N 0.000 claims description 2
• NQFMJRCAZHJLOZ-LLVKDONJSA-N CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H]2CNCCC2)=N1 Chemical compound CC1=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=NC(N[C@H]2CNCCC2)=N1 NQFMJRCAZHJLOZ-LLVKDONJSA-N 0.000 claims description 2
• NVMMSAKHSVYMTB-LLVKDONJSA-N CCN(CCC1)C[C@@H]1NC1=NC(C(F)(F)F)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C(F)(F)F)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 NVMMSAKHSVYMTB-LLVKDONJSA-N 0.000 claims description 2
• ZXAJMNIRVFYBTO-CQSZACIVSA-N CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C(C)=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C(C)=CC(C(F)(F)F)=C2)=C2O)N=N1 ZXAJMNIRVFYBTO-CQSZACIVSA-N 0.000 claims description 2
• OARGNKWIPJNHTG-GFCCVEGCSA-N CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C(F)=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)C[C@@H]1NC1=NC(C)=C(C(C(F)=CC(C(F)(F)F)=C2)=C2O)N=N1 OARGNKWIPJNHTG-GFCCVEGCSA-N 0.000 claims description 2
• KCEVLXXMPPVDGJ-KGLIPLIRSA-N CCN(C[C@@H](C1)NC2=NC(C)=C(C(C(C)=CC(C(F)(F)F)=C3)=C3O)N=N2)C[C@H]1O Chemical compound CCN(C[C@@H](C1)NC2=NC(C)=C(C(C(C)=CC(C(F)(F)F)=C3)=C3O)N=N2)C[C@H]1O KCEVLXXMPPVDGJ-KGLIPLIRSA-N 0.000 claims description 2
• XHZHNNGLOPCILP-OLZOCXBDSA-N CCN(C[C@@H](C1)NC2=NC(C)=C(C(C=CC(C(F)(F)F)=C3)=C3O)N=N2)C[C@H]1O Chemical compound CCN(C[C@@H](C1)NC2=NC(C)=C(C(C=CC(C(F)(F)F)=C3)=C3O)N=N2)C[C@H]1O XHZHNNGLOPCILP-OLZOCXBDSA-N 0.000 claims description 2
• NHADDZMCASKINP-HTRCEHHLSA-N decarboxydihydrocitrinin Natural products C1=C(O)C(C)=C2[C@H](C)[C@@H](C)OCC2=C1O NHADDZMCASKINP-HTRCEHHLSA-N 0.000 claims 2
• 239000000203 mixture Substances 0.000 abstract description 65
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 247
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 231
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
• 235000019439 ethyl acetate Nutrition 0.000 description 91
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
• 239000012044 organic layer Substances 0.000 description 76
• 239000011541 reaction mixture Substances 0.000 description 72
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 60
• 239000000243 solution Substances 0.000 description 57
• 239000012267 brine Substances 0.000 description 50
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 50
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 50
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 47
• 239000000741 silica gel Substances 0.000 description 43
• 229910002027 silica gel Inorganic materials 0.000 description 43
• 238000003818 flash chromatography Methods 0.000 description 41
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 40
• 239000012043 crude product Substances 0.000 description 37
• 239000007787 solid Substances 0.000 description 37
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 35
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 33
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
• 239000010410 layer Substances 0.000 description 31
• 229910052786 argon Inorganic materials 0.000 description 30
• 229910052938 sodium sulfate Inorganic materials 0.000 description 28
• 235000011152 sodium sulphate Nutrition 0.000 description 28
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
• BHFPRKFRNIWENF-UHFFFAOYSA-N 3,6-dichloro-5-methyl-1,2,4-triazine Chemical compound CC1=NC(Cl)=NN=C1Cl BHFPRKFRNIWENF-UHFFFAOYSA-N 0.000 description 24
• 229920006395 saturated elastomer Polymers 0.000 description 24
• 210000004027 cell Anatomy 0.000 description 20
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
• 239000011734 sodium Substances 0.000 description 18
• 238000002360 preparation method Methods 0.000 description 17
• 239000000047 product Substances 0.000 description 17
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
• GYGNUMOLFBSVCL-UHFFFAOYSA-N [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1O GYGNUMOLFBSVCL-UHFFFAOYSA-N 0.000 description 16
• 229910000027 potassium carbonate Inorganic materials 0.000 description 16
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 14
• 239000000843 powder Substances 0.000 description 14
• 230000004054 inflammatory process Effects 0.000 description 13
• 108090000426 Caspase-1 Proteins 0.000 description 12
• 239000003921 oil Substances 0.000 description 12
• 235000019198 oils Nutrition 0.000 description 12
• 102100035904 Caspase-1 Human genes 0.000 description 11
• 206010061218 Inflammation Diseases 0.000 description 11
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 11
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
• 206010039083 rhinitis Diseases 0.000 description 10
• 208000024827 Alzheimer disease Diseases 0.000 description 9
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• 208000018737 Parkinson disease Diseases 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 125000004432 carbon atom Chemical group C* 0.000 description 8
• 238000004440 column chromatography Methods 0.000 description 8
• 239000000706 filtrate Substances 0.000 description 8
• 239000012074 organic phase Substances 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 8
• 230000006806 disease prevention Effects 0.000 description 7
• 125000003386 piperidinyl group Chemical group 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 230000006010 pyroptosis Effects 0.000 description 7
• XBNRJKSGOLRSRX-UHFFFAOYSA-N (4-chloro-2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1O XBNRJKSGOLRSRX-UHFFFAOYSA-N 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
• 229920002261 Corn starch Polymers 0.000 description 6
• 229910004298 SiO 2 Inorganic materials 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 239000008120 corn starch Substances 0.000 description 6
• 239000013058 crude material Substances 0.000 description 6
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 6
• 239000006260 foam Substances 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 239000000454 talc Substances 0.000 description 6
• 229910052623 talc Inorganic materials 0.000 description 6
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
• PRPNZPPJPIEXJI-UHFFFAOYSA-N 2h-triazin-1-amine Chemical compound NN1NN=CC=C1 PRPNZPPJPIEXJI-UHFFFAOYSA-N 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 206010009900 Colitis ulcerative Diseases 0.000 description 5
• 208000011231 Crohn disease Diseases 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 108090000695 Cytokines Proteins 0.000 description 5
• 208000004454 Hyperalgesia Diseases 0.000 description 5
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical class CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 5
• 238000005481 NMR spectroscopy Methods 0.000 description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 description 5
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
• 229910000024 caesium carbonate Inorganic materials 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 230000030833 cell death Effects 0.000 description 5
• 208000015114 central nervous system disease Diseases 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 239000007903 gelatin capsule Substances 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 208000019423 liver disease Diseases 0.000 description 5
• 208000030159 metabolic disease Diseases 0.000 description 5
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• KOFNQIAWWVBBJZ-UHFFFAOYSA-N (4-fluoro-2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1O KOFNQIAWWVBBJZ-UHFFFAOYSA-N 0.000 description 4
• DPHNJPUOMLRELT-UHFFFAOYSA-N 2,3-dihydro-1h-inden-4-ol Chemical compound OC1=CC=CC2=C1CCC2 DPHNJPUOMLRELT-UHFFFAOYSA-N 0.000 description 4
• AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• KLEVMCIEFMJURW-UHFFFAOYSA-N CC(N=C(NC1C(CCC2)N2CCC1)N=N1)=C1Cl Chemical compound CC(N=C(NC1C(CCC2)N2CCC1)N=N1)=C1Cl KLEVMCIEFMJURW-UHFFFAOYSA-N 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• 208000009329 Graft vs Host Disease Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 208000026594 alcoholic fatty liver disease Diseases 0.000 description 4
• 206010053552 allodynia Diseases 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 208000030533 eye disease Diseases 0.000 description 4
• 208000024908 graft versus host disease Diseases 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 230000001926 lymphatic effect Effects 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
• 239000003208 petroleum Substances 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 229920005862 polyol Polymers 0.000 description 4
• 150000003077 polyols Chemical class 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 208000017520 skin disease Diseases 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 238000004808 supercritical fluid chromatography Methods 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
• 208000008589 Obesity Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 239000012979 RPMI medium Substances 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 235000003599 food sweetener Nutrition 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 238000012417 linear regression Methods 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 235000020824 obesity Nutrition 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 208000023504 respiratory system disease Diseases 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 230000037432 silent mutation Effects 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000003765 sweetening agent Substances 0.000 description 3
• AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 3
• LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• LKKCSUHCVGCGFA-KGZKBUQUSA-N (1r,2r)-2-aminocyclohexan-1-ol;hydrochloride Chemical compound Cl.N[C@@H]1CCCC[C@H]1O LKKCSUHCVGCGFA-KGZKBUQUSA-N 0.000 description 2
• WAKUKXKZEXFXJP-SSDOTTSWSA-N (3r)-1-ethylpiperidin-3-amine Chemical compound CCN1CCC[C@@H](N)C1 WAKUKXKZEXFXJP-SSDOTTSWSA-N 0.000 description 2
• 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 2
• DPBJLNMVJTYHJR-UHFFFAOYSA-N 1,2,3,5,6,7,8,8a-octahydroindolizin-6-amine Chemical compound C1C(N)CCC2CCCN21 DPBJLNMVJTYHJR-UHFFFAOYSA-N 0.000 description 2
• WAKUKXKZEXFXJP-UHFFFAOYSA-N 1-ethylpiperidin-3-amine Chemical compound CCN1CCCC(N)C1 WAKUKXKZEXFXJP-UHFFFAOYSA-N 0.000 description 2
• 238000005160 1H NMR spectroscopy Methods 0.000 description 2
• IMHHWOCMTWWBAQ-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-4-ol Chemical compound OC1=CC=CC2=C1CCO2 IMHHWOCMTWWBAQ-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• HUESCFUGEVOOKM-UHFFFAOYSA-N 2-bromo-6-fluoro-4-(trifluoromethyl)aniline Chemical compound BrC1=C(N)C(=CC(=C1)C(F)(F)F)F HUESCFUGEVOOKM-UHFFFAOYSA-N 0.000 description 2
• HEPPAPZASXFWTB-UHFFFAOYSA-N 3,3-dibromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)C(Br)Br HEPPAPZASXFWTB-UHFFFAOYSA-N 0.000 description 2
• SZQSVGZFSOUXPL-UHFFFAOYSA-N 3-amino-1-methylcyclobutan-1-ol;hydrochloride Chemical compound Cl.CC1(O)CC(N)C1 SZQSVGZFSOUXPL-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• RMMXULAVPASGOF-UHFFFAOYSA-N 5-(trifluoromethyl)-1,2,4-triazin-3-amine Chemical compound NC1=NN=CC(C(F)(F)F)=N1 RMMXULAVPASGOF-UHFFFAOYSA-N 0.000 description 2
• NYNXSSNRGVPJEV-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran-4-ol Chemical compound C1=C(Br)C(O)=C2CCOC2=C1 NYNXSSNRGVPJEV-UHFFFAOYSA-N 0.000 description 2
• XOCGDRSTHARVQH-UHFFFAOYSA-N 5-bromo-4-phenylmethoxy-2,3-dihydro-1H-indene Chemical compound BrC1=CC=C(CCC2)C2=C1OCC1=CC=CC=C1 XOCGDRSTHARVQH-UHFFFAOYSA-N 0.000 description 2
• IIMYSUKDSQYYER-UHFFFAOYSA-N 6-bromo-3-chloro-1,2,4-triazine Chemical compound ClC1=NC=C(Br)N=N1 IIMYSUKDSQYYER-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
• 208000009304 Acute Kidney Injury Diseases 0.000 description 2
• 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• MZABKTKQWHEUDR-UHFFFAOYSA-N CC(C1)(CC1NC(N=N1)=NC(C)=C1Cl)O Chemical compound CC(C1)(CC1NC(N=N1)=NC(C)=C1Cl)O MZABKTKQWHEUDR-UHFFFAOYSA-N 0.000 description 2
• RRDOLVHSMNKNNK-UHFFFAOYSA-N CC1(C)OB(C(C=CC2=C3CCC2)=C3O)OC1(C)C Chemical compound CC1(C)OB(C(C=CC2=C3CCC2)=C3O)OC1(C)C RRDOLVHSMNKNNK-UHFFFAOYSA-N 0.000 description 2
• WJYUOHWMNQWAOS-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(CCC3)C3=C2OCC2=CC=CC=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(CCC3)C3=C2OCC2=CC=CC=C2)OC1(C)C WJYUOHWMNQWAOS-UHFFFAOYSA-N 0.000 description 2
• UDVCWQKCKHTAQM-UHFFFAOYSA-N CCN(CCC1)CC1NC(N=N1)=NC(C)=C1Cl Chemical compound CCN(CCC1)CC1NC(N=N1)=NC(C)=C1Cl UDVCWQKCKHTAQM-UHFFFAOYSA-N 0.000 description 2
• 201000003274 CINCA syndrome Diseases 0.000 description 2
• MZVCYJFQKAUDNB-UHFFFAOYSA-N C[Si](C)(C)CCOCOC(C1=C(C=C2)OCC1)=C2Br Chemical compound C[Si](C)(C)CCOCOC(C1=C(C=C2)OCC1)=C2Br MZVCYJFQKAUDNB-UHFFFAOYSA-N 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 208000035690 Familial cold urticaria Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 102100037907 High mobility group protein B1 Human genes 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 108010034143 Inflammasomes Proteins 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 201000002795 Muckle-Wells syndrome Diseases 0.000 description 2
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• BGLHVSLTJBWJNS-UHFFFAOYSA-N NC(N=N1)=NC(C(F)(F)F)=C1Br Chemical compound NC(N=N1)=NC(C(F)(F)F)=C1Br BGLHVSLTJBWJNS-UHFFFAOYSA-N 0.000 description 2
• 102000012064 NLR Proteins Human genes 0.000 description 2
• 108091008099 NLRP3 inflammasome Proteins 0.000 description 2
• 108091005686 NOD-like receptors Proteins 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 208000033626 Renal failure acute Diseases 0.000 description 2
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• RQCNMAAZFRLTGZ-UHFFFAOYSA-N [2-hydroxy-4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1O RQCNMAAZFRLTGZ-UHFFFAOYSA-N 0.000 description 2
• FQEYWPBUQBRXSW-UHFFFAOYSA-N [2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]boronic acid Chemical compound OC1=C(C(=CC(=C1)C(F)(F)F)C)B(O)O FQEYWPBUQBRXSW-UHFFFAOYSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 201000011040 acute kidney failure Diseases 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 208000002205 allergic conjunctivitis Diseases 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 239000003124 biologic agent Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000001143 conditioned effect Effects 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 238000005661 deetherification reaction Methods 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 230000000694 effects Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 229910052736 halogen Inorganic materials 0.000 description 2
• 150000002367 halogens Chemical class 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• VLECDMDGMKPUSK-UHFFFAOYSA-N hydron;piperidin-3-ol;chloride Chemical compound Cl.OC1CCCNC1 VLECDMDGMKPUSK-UHFFFAOYSA-N 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
• 229940011051 isopropyl acetate Drugs 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 2
• 239000012299 nitrogen atmosphere Substances 0.000 description 2
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• QZSACHHNFDNCNB-ZCFIWIBFSA-N (3r)-1-methylpiperidin-3-amine Chemical compound CN1CCC[C@@H](N)C1 QZSACHHNFDNCNB-ZCFIWIBFSA-N 0.000 description 1
• OTXHZHQQWQTQMW-UHFFFAOYSA-N (diaminomethylideneamino)azanium;hydrogen carbonate Chemical compound OC([O-])=O.N[NH2+]C(N)=N OTXHZHQQWQTQMW-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• SHXUPEAVNUWGDU-UHFFFAOYSA-N 1,2,3,5,6,7,8,8a-octahydroindolizin-8-amine Chemical compound NC1CCCN2CCCC12 SHXUPEAVNUWGDU-UHFFFAOYSA-N 0.000 description 1
• ARHDUOQIXLGANT-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1F ARHDUOQIXLGANT-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• HVRDGWNRSZJAMJ-UHFFFAOYSA-N 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)phenol Chemical compound CC=1C(=C(C=C(C=1)C(F)(F)F)O)B1OC(C(O1)(C)C)(C)C HVRDGWNRSZJAMJ-UHFFFAOYSA-N 0.000 description 1
• NOMQPDVXZMLJID-UHFFFAOYSA-N 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-amine Chemical compound NC1CCCN2C=CN=C12 NOMQPDVXZMLJID-UHFFFAOYSA-N 0.000 description 1
• KFLWBZPSJQPRDD-ONEGZZNKSA-N 5-[(e)-2-nitroethenyl]-1,3-benzodioxole Chemical compound [O-][N+](=O)\C=C\C1=CC=C2OCOC2=C1 KFLWBZPSJQPRDD-ONEGZZNKSA-N 0.000 description 1
• WIBIPFPOGMLYJQ-UHFFFAOYSA-N 6-bromo-1,2,4-triazin-3-amine Chemical compound NC1=NC=C(Br)N=N1 WIBIPFPOGMLYJQ-UHFFFAOYSA-N 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000026326 Adult-onset Still disease Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 239000004475 Arginine Chemical class 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• 208000006740 Aseptic Meningitis Diseases 0.000 description 1
• 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
• PVNAGTOHGVZXOK-UHFFFAOYSA-N CC(C)(C)N(CCC1)CC1NC1=NC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CC(C)(C)N(CCC1)CC1NC1=NC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 PVNAGTOHGVZXOK-UHFFFAOYSA-N 0.000 description 1
• KPVLCFZNFULSIF-UHFFFAOYSA-N CC(N=C(NC1C2=NC=CN2CCC1)N=N1)=C1Cl Chemical compound CC(N=C(NC1C2=NC=CN2CCC1)N=N1)=C1Cl KPVLCFZNFULSIF-UHFFFAOYSA-N 0.000 description 1
• NVSGQQUNHZIIMT-UHFFFAOYSA-N CC(N=C(NC1CN(CCC2)C2CC1)N=N1)=C1Cl Chemical compound CC(N=C(NC1CN(CCC2)C2CC1)N=N1)=C1Cl NVSGQQUNHZIIMT-UHFFFAOYSA-N 0.000 description 1
• XILGJPIJMVHNKU-UHFFFAOYSA-N CC1(C)OB(C(C=CC2=C3CCO2)=C3OCOCC[Si](C)(C)C)OC1(C)C Chemical compound CC1(C)OB(C(C=CC2=C3CCO2)=C3OCOCC[Si](C)(C)C)OC1(C)C XILGJPIJMVHNKU-UHFFFAOYSA-N 0.000 description 1
• QTCCGJFDRWCEBM-UHFFFAOYSA-N CC1(C)OB(C2=CC(C(F)(F)F)=CC(F)=C2N)OC1(C)C Chemical compound CC1(C)OB(C2=CC(C(F)(F)F)=CC(F)=C2N)OC1(C)C QTCCGJFDRWCEBM-UHFFFAOYSA-N 0.000 description 1
• RWLRXHCVIHDIHX-UHFFFAOYSA-N CCN(CCC1)CC1NC1=CC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound CCN(CCC1)CC1NC1=CC(C)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 RWLRXHCVIHDIHX-UHFFFAOYSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 102000004091 Caspase-8 Human genes 0.000 description 1
• 108090000538 Caspase-8 Proteins 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
• 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 241000400611 Eucalyptus deanei Species 0.000 description 1
• 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
• 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 102100037388 Gasdermin-D Human genes 0.000 description 1
• 101710087939 Gasdermin-D Proteins 0.000 description 1
• 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
• 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
• 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
• 102100027670 Islet amyloid polypeptide Human genes 0.000 description 1
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
• 208000009388 Job Syndrome Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• 206010024227 Lepromatous leprosy Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Chemical class 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 206010027201 Meningitis aseptic Diseases 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 1
• CMGCIHCPWBDSHZ-UHFFFAOYSA-N NC1=NC(C(F)(F)F)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 Chemical compound NC1=NC(C(F)(F)F)=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 CMGCIHCPWBDSHZ-UHFFFAOYSA-N 0.000 description 1
• 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 1
• 101150061038 NLRP3 gene Proteins 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 208000000450 Pelvic Pain Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
• 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 101710115313 Pyrin domain-containing protein 3 Proteins 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 206010039088 Rhinitis atrophic Diseases 0.000 description 1
• 208000036284 Rhinitis seasonal Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• 208000009714 Severe Dengue Diseases 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 210000000068 Th17 cell Anatomy 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000010085 airway hyperresponsiveness Effects 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical class OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229960001838 canakinumab Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000006721 cell death pathway Effects 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 208000002849 chondrocalcinosis Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000023819 chronic asthma Diseases 0.000 description 1
• 201000009151 chronic rhinitis Diseases 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 229910052681 coesite Inorganic materials 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• 229910052906 cristobalite Inorganic materials 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 150000001930 cyclobutanes Chemical group 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• LTYUZQJKSFOCGG-UHFFFAOYSA-L dicesium argon carbonate Chemical compound [Cs+].[Ar].C([O-])([O-])=O.[Cs+] LTYUZQJKSFOCGG-UHFFFAOYSA-L 0.000 description 1
• AGCOMFFHXJMNLN-UHFFFAOYSA-N dichloromethane;dihydrochloride Chemical compound Cl.Cl.ClCCl AGCOMFFHXJMNLN-UHFFFAOYSA-N 0.000 description 1
• 235000013681 dietary sucrose Nutrition 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 208000001606 epiglottitis Diseases 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000024711 extrinsic asthma Diseases 0.000 description 1
• 208000029944 familial hemophagocytic lymphohistiocytosis type 1 Diseases 0.000 description 1
• 201000007249 familial juvenile hyperuricemic nephropathy Diseases 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960001031 glucose Drugs 0.000 description 1
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000019189 interleukin-1 beta production Effects 0.000 description 1
• 230000024949 interleukin-17 production Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 201000010659 intrinsic asthma Diseases 0.000 description 1
• 229960004903 invert sugar Drugs 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
• 229940069510 parthenolide Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• OXDLBBKNAAFZNI-UHFFFAOYSA-N phenol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC1=CC=CC=C1 OXDLBBKNAAFZNI-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 201000000317 pneumocystosis Diseases 0.000 description 1
• 229920000768 polyamine Chemical class 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• ZPATUOFYXSBHMN-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [H+].[H+].[H+].[Br-].[Br-].[Br-].C1=CC=NC=C1 ZPATUOFYXSBHMN-UHFFFAOYSA-N 0.000 description 1
• 230000009873 pyroptotic effect Effects 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 208000009169 relapsing polychondritis Diseases 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 206010038464 renal hypertension Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960001886 rilonacept Drugs 0.000 description 1
• 108010046141 rilonacept Proteins 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 208000008742 seborrheic dermatitis Diseases 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 229910052682 stishovite Inorganic materials 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• ACHGEWOGBWGEEL-JGVFFNPUSA-N tert-butyl n-[(3r,5s)-5-fluoropiperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CNC[C@@H](F)C1 ACHGEWOGBWGEEL-JGVFFNPUSA-N 0.000 description 1
• IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
• 239000012414 tert-butyl nitrite Substances 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 229910052905 tridymite Inorganic materials 0.000 description 1
• 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical class CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000001319 vasomotor rhinitis Diseases 0.000 description 1
• 201000005539 vernal conjunctivitis Diseases 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 238000013389 whole blood assay Methods 0.000 description 1